Medication safety in patients with hepatic impairment: A survey of community pharmacists’ knowledge level and their practice in caring for these patients by Weersink, R.A. (Rianne A.) et al.
OR I G I N A L A R T I C L E
Medication safety in patients with hepatic impairment: A
survey of community pharmacists’ knowledge level and their
practice in caring for these patients
Rianne A. Weersink1,2 | Marianna Abadier1,3 | Anthonius de Boer3,4 |
Katja Taxis2 | Sander D. Borgsteede1,5
1Department of Clinical Decision Support,
Health Base Foundation, Houten, The
Netherlands
2Department of Pharmacy, Unit of
Pharmacotherapy, -Epidemiology &
-Economics, University of Groningen,
Groningen, The Netherlands
3Department of Pharmaceutical Sciences,
University of Utrecht, Utrecht, The
Netherlands
4Dutch Medicines Evaluation Board (CBG-
MEB), Utrecht, The Netherlands
5Department of Hospital Pharmacy, Erasmus
University Medical Center, Rotterdam, The
Netherlands
Correspondence
Rianne A. Weersink, Department of Pharmacy,
Unit of Pharmacotherapy, -Epidemiology &
-Economics, University of Groningen,
Groningen, The Netherlands.
Email:r.a.weersink@rug.nl
Present address
Marianna Abadier, Mental Health Organisation
Rivierduinen, Lisse and Leiden, The
Netherlands.
Aims: To study community pharmacists' level of knowledge on medication safety in
patients with hepatic impairment and their practice in caring for these patients.
Methods: Pharmacists from Dutch community pharmacies (n = 1545) were invited to
participate in an online survey. The survey consisted of 27 questions covering 2 main
topics: knowledge and current practice. The level of knowledge was measured by a
6-item knowledge test. Multiple linear regression was used to identify predictors of
correctly answered responses.
Results: In total, 338 pharmacists (22%) completed the questionnaire. The mean
knowledge score was 2.8 (standard deviation 1.6). Only 30.3% of respondents were
able to appropriately advise on use of analgesics in severe cirrhosis. Postgraduate
education on hepatic impairment, knowledge of recently developed practical guid-
ance, and fewer years of practice were associated with a higher level of knowledge.
In total, 70.4% indicated to evaluate medication safety in a patient with hepatic
impairment at least once weekly. In the past 6 months, 83.3% of respondents consul-
ted a prescriber about a patient with hepatic impairment. Frequently encountered
barriers in practice were insufficient knowledge on the topic and a lack of essential
patient information (i.e. diagnosis and severity of the impairment).
Conclusion: Community pharmacists regularly evaluate the safety of medication in
patients with hepatic impairment, yet their level of knowledge was insufficient and
additional education is needed. Pharmacists experienced several difficulties in provid-
ing pharmaceutical care. If these issues are resolved, pharmacists can play a more
active role in ensuring medication safety in their patients with hepatic impairment.
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1 | INTRODUCTION
Patients with hepatic impairment are prone to develop adverse drug
reactions due to changes in the pharmacokinetics and pharmacody-
namics of medicines.1,2 Research showed that nearly 30% of patients
with liver cirrhosis, the advanced stage of all chronic liver diseases,
experience adverse drug reactions.3 A Dutch study showed that
almost 2/3 of patients with liver cirrhosis used potentially unsafe
drugs.4 In addition, a recent study among 57 patients with cirrhosis
identified a median of 6 medication-related problems per patient.5
Almost 60% of these problems could be resolved during a pharmacist-
led medication review. This suggests that pharmacists, as medication
experts, could play a key role in preventing and resolving medication-
related problems in this vulnerable patient group.
A barrier for pharmacists to fulfil this role was the lack of con-
crete prescribing recommendations for patients with hepatic impair-
ment and deficiencies in the information for these patients in the
product labels.6-9 However, in 2018, practical guidance for safe drug
use in this specific patient group was published.10,11 In the Nether-
lands, the website containing all guidance (www.drugsinlivercirrhosis.
org) has been available since 2017. Furthermore, the guidance was
integrated in all relevant clinical decision support systems (CDSS) used
in Dutch community pharmacies. Implementing changes in practice
may take time and pharmacists might encounter difficulties in prac-
tice.12 For example, a substantial part of the recommendations
depends on the severity of hepatic impairment, being expressed using
the Child–Turcotte–Pugh classification.10,13 Therefore, it is important
that this severity class is registered in the medical and pharmaceutical
record of a patient and exchanged between relevant healthcare pro-
viders. In addition, pharmacists need to be familiar with the recom-
mendations and have sufficient knowledge about the topic to be able
to interpret and apply the information in their practice.
Previous work focussed on knowledge and practices of physicians
in prescribing analgesics for patients with chronic liver disease.14-16
Little is known about the knowledge of community pharmacists on
safe medication use in patients with hepatic impairment. A few stud-
ies have described the care provided by pharmacists for a subgroup of
patients: those with viral hepatitis C,17-19 but those studies focussed
on clinical pharmacists or described care in only 1 clinic. Therefore,
this study aimed to determine the level of knowledge of community
pharmacists on medication safety in patients with hepatic impairment
and their practice in caring for this patient group.
2 | METHODS
2.1 | Study setting
In the Netherlands, patients are usually registered with 1 general prac-
titioner (GP) and 1 community pharmacy.20 The GP keeps a medical
record per patient and the pharmacist a pharmaceutical record. In
general, these are electronic records which operate a CDSS. Clinical
risk management of medication use is an important activity of Dutch
community pharmacists.21 In case the CDSS generates a medication
safety alert (e.g. contraindications, drug–drug interactions), the phar-
macist assesses the clinical relevance of the alert and if applicable,
takes action (e.g. inform the patients, adjust the dose or switch drugs
in cooperation with the GP).
2.2 | Study population
We conducted a cross-sectional survey among pharmacists from
the Utrecht Pharmacy Practice network for Education and Research
(UPPER) network. The UPPER network consists of 1545 community
pharmacies, representing 75% of all community pharmacies in the
Netherlands at the time the survey was performed.22 An invitation
for the pharmacist to participate in the electronic survey was sent
in March 2018, one and a half years after the implementation of
the first safety and dosing advices in cirrhosis.10 A reminder was
sent 2 weeks later and the questionnaire was closed 2 weeks
thereafter. As an incentive, all respondents were given the option
to receive additional information about “pharmaceutical care in
patients with hepatic impairment” by providing their email address
at the end. The survey was conducted with Survey Monkey soft-
ware. It was approved by the UPPER Institutional Review Board of
Utrecht University (number: UPF1801).
2.3 | Survey
The survey consisted of 27 questions covering 2 main topics: knowl-
edge and current practice and can be found in the Supplementary
What is already known about this subject
• Patients with hepatic impairment have an increased risk
of medication-related problems due to alterations in
pharmacokinetics and pharmacodynamics of medicines.
• Pharmacists could play a key role in preventing and
resolving medication-related problems in this vulnerable
patient group.
What this study adds
• Community pharmacists frequently evaluated the safety
of a medicine in patients with hepatic impairment.
• The level of knowledge of pharmacists on medication
safety in patients with hepatic impairment was limited
and more education on the topic is needed and wanted.
• Community pharmacists experienced limited access to
relevant patient data (e.g. diagnosis and severity of
hepatic impairment) which may adversely affect their
practice.
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Data. The questionnaire was developed by the authors with expertise
in hepatic impairment and pharmacy practice, and piloted among 13
pharmacists. We refined the questionnaire based on the pilot: we
adjusted the formulation of some answers and changed the order of
the questions slightly.
The topic knowledge was divided into self-perceived knowledge
of pharmacists, questions on educational needs and a brief knowl-
edge test. Self-perceived knowledge was tested by 4 statements
where pharmacists recorded their agreement on a 5-point Likert
scale. To investigate educational needs, we asked the pharmacists
about the training they received on medication safety in patients
with hepatic impairment and if they wished to receive additional
education. The knowledge test consisted of 6 multiple-choice ques-
tions and the participants were instructed to complete those without
using reference works.
The topic of current practice was covered with questions on how
often the pharmacists encountered a medication safety alert from
their CDSS about a patient with hepatic impairment, the familiarity of
pharmacists with the new recommendations and website,10 and ques-
tions about contact with other healthcare professionals. To include
potential topics that were not covered by the survey, we added 3
open-ended questions about current practice and difficulties experi-
enced in providing pharmaceutical care to patients with hepatic
impairment at the end of the questionnaire.
2.4 | Data analysis
We used both descriptive and inferential statistics to analyse the data.
Due to missing values, the number of respondents per question varied
and, where appropriate, the absolute number of respondents per
questions was listed. In total, <5% of items were missing. Due to the
low rate scoring of some of the multiple-choice questions, we merged
responses from selected questions into fewer categories. The state-
ments on knowledge were recoded from a 5-point Likert scale into a
3-level scale: strongly disagree/disagree, neutral, agree/strongly agree.
The answers on the frequency of a medication safety alert were
recoded into often (daily/weekly) and rarely (monthly/less than once a
month). The answers countryside and village from the variable location
of pharmacy were combined into village or countryside. Answers to the
question about the community pharmacy registration were merged
into registered as community pharmacist and not (yet) registered as com-
munity pharmacist.
The outcome of the knowledge test was the number of cor-
rectly answered questions, with a maximum of 6. Univariate analyses
were performed for all potential explanatory variables. The vari-
ables age and years of practice were highly correlated and there-
fore only 1 variable (i.e. years of practice) was included in the
analysis. After univariate analyses, variables with P-values <.25
were included in multiple linear regression analysis. Cases with
missing data were deleted pairwise. A P-value <.05 was considered
statistically significant. The analyses were performed with SPSS,
version 25.
3 | RESULTS
In total, 338 pharmacists (22%) completed the survey of the 1545
pharmacies the invitation was sent to. The characteristics of the
respondents are presented in Table 1. Respondents were predomi-
nantly female pharmacists, working in a community pharmacy in an
urban area.
3.1 | Knowledge
Respondents were asked about their self-perceived knowledge on
medication safety in hepatic impairment (Figure 1). A minority of
pharmacists (20.4%) perceived their knowledge about the influence
of hepatic impairment on medication as sufficient, and 29.0% indi-
cated that they were able to interpret hepatic laboratory values. In
total, 69.6% (n = 218) of respondents received prior education on
medication safety in hepatic impairment. Almost half (44.1%;
n = 138) of pharmacists received training while in pharmacy school,
and 18.2% (n = 57) during their 2-year registration period as com-
munity pharmacist. A total of 42.8% (n = 134) received education
during a postgraduate course or a pharmacotherapy meeting.
Almost all respondents (90.7%; n = 284) expressed a wish for addi-
tional education on this topic.
The mean score of the respondents on the knowledge test was
2.8 (standard deviation 1.6) correct answers out of 6 questions (mode
2.0). Fifteen respondents (4.7%) were able to answer all 6 questions
correctly, and 6.3% answered all incorrectly (n = 20). As can be seen in
TABLE 1 Characteristics of the respondents
n (%)
Sexa
Female 207 (66.6)
Male 104 (33.4)
Age (y)a, mean ± SD 42 ± 11
Registered as community pharmacistb
Yes 274 (89.8)
No or not yet 31 (10.2)
Years of practiceb, median (IQR) 15 (7–25)
≤10 112 (36.7)
11–20 98 (32.1)
21–30 67 (22.0)
≥31 28 (9.2)
Practice settinga
Community pharmacy 295 (94.9)
Outpatient pharmacy 16 (5.1)
Location of pharmacyb
Urban area 190 (62.3)
Village or countryside 115 (37.7)
SD, standard deviation; IQR, interquartile range.
anumber of respondents is 311;
bnumber of respondents is 305
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Table 2, 77.6% of pharmacists did not know which laboratory parame-
ters are used to assess hepatic function, and 69.7% were not able to
give a proper analgesic advice in a patient with severe cirrhosis. By
contrast, 64.0% of the pharmacists were familiar with the Child–Pugh
classification, and 61.8% knew that medication adjustments are only
needed in patients with cirrhosis and not (yet) in patients with viral
hepatitis or steatosis.
In multiple linear regression analysis, 3 variables were associated
with the total knowledge score (Table 3). Higher knowledge scores
were associated with postgraduate education or a pharmacotherapy
meeting on hepatic impairment (P < .001) and familiarity with the new
recommendations or website (P < .001). A higher total knowledge
score was also negatively correlated to years of practice (P < .001).
F IGURE 1 Self-perceived
knowledge on medication safety in
hepatic impairment among
pharmacists (n = 338)
TABLE 2 An overview of the knowledge test containing the
questions, the correct and incorrect answers (n = 317)
QUESTION n (%)
Which laboratory parameters are used to assess liver function?
Correct: Albumin, bilirubin and INR 71 (22.4)
Incorrect 246 (77.6)
Gamma-GT and alkaline phosphatase 17 (5.4)
ASAT and ALAT 210 (66.2)
Lactate dehydrogenase and ammonia 1 (0.3)
I do not know 18 (5.7)
Which classification is used to estimate the severity of
hepatic impairment?
Correct: Child–Pugh 203 (64.0)
Incorrect 114 (36.0)
ASAT/ALAT ratio 31 (9.8)
Hy's law 0 (0)
None of the above answers 7 (2.2)
I do not know 76 (24.0)
In which of the following diseases is the impairment of
hepatic function clinically relevant for medication use?
Correct: Liver cirrhosis 196 (61.8)
Incorrect 121 (38.2)
Viral hepatitis 1 (0.3)
Steatosis hepatis (fatty liver) 2 (0.6)
All 3 answers mentioned 80 (25.2)
None of the above answers 2 (0.6)
I do not know 36 (11.4)
What do you do if a GP adds the contraindication “hepatic
impairment” in the medical record of a patient because of a
liver cyst?
Correct: The contraindication is irrelevant,
I remove it in consultation with the GP
165 (52.1)
Incorrect 152 (47.9)
The contraindication is relevant, I do not do
anything
19 (6.0)
I do not know what to do 133 (42.0)
(Continues)
TABLE 2 (Continued)
QUESTION n (%)
A physician asks your advice on pain relief in a
patient with arthrosis and severe liver cirrhosis.
Which analgesic would you certainly not
recommend?
Correct: Diclofenac 96 (30.3)
Incorrect 221 (69.7)
Acetaminophen (paracetamol) 140 (44.2)
Tramadol 12 (3.8)
Morphine 19 (6.0)
I do not know 50 (15.8)
Which pharmacokinetic process (es) are affected
by hepatic impairment?
Correct: All of the pharmacokinetic processes 158 (49.8)
Incorrect 159 (50.2)
Absorption 0 (0)
Distribution 0 (0)
Metabolism 125 (39.4)
Excretion 19 (6.0)
No influence on pharmacokinetics 0 (0)
I do not know 15 (4.7)
ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; GP,
general practitioner; GT, glutamyltransferase; INR, international
normalized ratio
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3.2 | Current practice
Seventy percent of pharmacists indicated to encounter at least once a
week a medication safety alert from their CDSS concerning a patient
with hepatic impairment (Table 4). A proportion of 53.4% were famil-
iar with the new alerts in their CDSS. A total of 55.4% were aware of
the website with advice about medication safety in cirrhosis.
Among healthcare professionals, the GP was most often consul-
ted with a question about a prescription in a patient with hepatic
impairment. A total of 71.3% of respondents contacted a prescriber in
the past 6 months to retrieve the severity of a patient's hepatic
impairment. More than half of these respondents experienced difficul-
ties during that contact. In an open question, pharmacists explained
these difficulties. A frequently mentioned remark was the lack of rele-
vant patient information (e.g. severity of hepatic impairment or diag-
nosis of cirrhosis): “General practitioners become irritated when I ask for
a patient's renal function, let alone when I also ask which patients have
cirrhosis.” (Female, age 63 years). Respondents also indicated that
there was a lack of knowledge on this topic: “My general practitioners
have no idea what hepatic impairment exactly means. The contraindica-
tion hepatic impairment is registered while the patient ‘only’ had an
increase in ALAT and/or ASAT.” (Female, age 36 years).
Another open-ended question asked about the role of pharma-
cists in caring for patients with hepatic impairment. Overall, there
was a sense of willingness amongst respondents to take responsibil-
ity in ensuring optimal medication use in patients with hepatic
impairment: “Our role is to provide information about the use of medi-
cation when a patient has hepatic impairment and the possible conse-
quences.” (Female, age 57 years).
4 | DISCUSSION
This study is unique in assessing community pharmacists' level of
knowledge on medication safety in patients with hepatic impairment
and their practice in caring for these patients. We demonstrated that
70% of the respondents evaluated the safety of a medicine in a patient
with hepatic impairment at least once a week and <80% consulted a
prescriber in the past 6 months with a medication safety question.
However, the pharmacists' knowledge level—subjective and objective—
was insufficient and they expressed a wish for additional education.
Furthermore, pharmacists experienced difficulties in caring for these
patients due to problems in the contact with prescribers and limited
access to essential patient data, like the severity of hepatic impairment.
Pharmacists had limited knowledge on different topics of pharma-
ceutical care in hepatic impairment. Strikingly, only about 1/5 of
respondents knew which laboratory parameters are used to evaluate
TABLE 3 Multiple linear regression analysis of variables associated with total knowledge score. Variables predicting knowledge levels of
pharmacists in a multiple linear regression model (n = 305)
Predictors Coefficient (β) SE 95% CI P-value
[intercept] 2.019 0.192
Years of practicea −0.029 0.008 −0.045 −0.014 <.001
Postgraduate education course or pharmacotherapy
meeting
0.720 0.161 0.403 1.037 <.001
Familiar with new recommendations or website 1.372 0.171 1.035 1.709 <.001
Adjusted R2 = 0.27. SE, standard error; 95% CI, 95% confidence intervals of the coefficients.
ayears of practice was included as continuous variable in the analysis.
TABLE 4 Current practice among pharmacists in caring for
patients with hepatic impairment
n (%)
Often (daily/
weekly)
Rarely (monthly
or less)
How often do you encounter
a hepatic impairment
medication safety alert in
your CDSS?
238 (70.4) 100 (29.3)
Yes No
Familiarity with new CDSS
alerts or website
218 (69.6) 95 (30.4)
Are you familiar with the
new CDSS alerts?
167 (53.4) 146 (46.6)
Are you familiar with the
website?
173 (55.4) 139 (44.6)
In the past 6 months, have
you consulted 1 of the
following prescribers with
a question about medication
safety in a patient with
hepatic impairment?
279 (83.3) 56 (16.7)
General practitioner 262 (78.2) 73 (21.8)
Gastroenterologist 86 (25.7) 249 (74.3)
Other prescriber 54 (16.1) 281 (83.9)
In the past 6 months, have you
consulted a prescriber about
a patient's severity of hepatic
impairment?
239 (71.3) 96 (28.7)
If yes, did you encounter
difficulties during that
contact?
135 (56.7) 103 (43.3)
Number of respondents varied per question from 312–338 and n = 238
for the last question. CDSS, clinical decision support system.
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hepatic function. In addition, a large proportion of pharmacists was
not able to give correct advice on analgesic use in severe cirrhosis.
Knowledge of pharmacists on this topic does not seem to have been
assessed previously, yet a few studies evaluated physicians' practices
in prescribing analgesics in patients with cirrhosis.14-16 These studies
found similar results: an overall limited knowledge on the topic. Possi-
ble explanations for this finding are that medication safety in hepatic
impairment is a rather complex topic. Gastroenterologists, specialized
in caring for these patients, also knew more often which analgesic
was safe to prescribe compared to nongastroenterologists.14 In addi-
tion, the former lack of practical guidance possibly contributed to the
low knowledge level. This lack of guidance probably also limited the
quantity and quality of education on the topic: less than half of the
respondents in our survey had some training in hepatic impairment
during their pharmacy degree. These results mark the need for addi-
tional or higher quality education about medication safety in hepatic
impairment. The respondents in our study who took a postgraduate
course also had a higher score on the knowledge test, possibly indicat-
ing the effect of additional education. However, we do not know how
recently the respondents took this course and how often they took a
postgraduate course on this topic.
Pharmacists with less years in practice scored higher on the
knowledge test. Previous studies assessing healthcare professionals'
knowledge on other topics (e.g. [pharmaco]genetics) also showed that
more recent graduation was related to higher knowledge scores.23,24
Recent graduates probably remember most from the education
received during pharmacy school or their registration period and may
be more willing to learn. Also notable was the association between
familiarity with the new recommendations in the CDSS or the website
and a higher score on the knowledge test. Participants familiar with
the website or recommendations are possibly more interested in the
topic and might have read background information about medication
safety in patients with hepatic impairment.
When consulting prescribers about patients with hepatic impair-
ment, more than half of the pharmacists experienced difficulties dur-
ing that contact. One of the difficulties mentioned was the lack of
relevant patient information, i.e. data on the diagnosis and the sever-
ity of hepatic impairment. This can partly be explained by the complex
classification used to grade the severity of hepatic impairment (i.e. the
Child–Pugh classification13). This classification consists of 5 parame-
ters and 2 of these include clinical symptoms (i.e. degree of ascites
and of hepatic encephalopathy). Pharmacists cannot determine the
severity of hepatic impairment themselves and need the information
from physicians. Exchange of relevant patient data between physi-
cians and pharmacists is therefore necessary. Warholak et al. showed
that pharmacists were able to give better pharmaceutical support
when they had a more complete overview of a patient's medical
record.25 Furthermore, a review on clinical decision support noted
that drug-disease interaction alerts could only work if the diagnoses
and conditions of a patient, even as the degree of impairment have
been accurately entered into the medical or pharmaceutical record of
a patient.26 Efforts are needed to improve exchange of these patient
data.
4.1 | Limitations
The current study achieved a response rate of 22%. Because there
are also general pharmacy email addresses included in the UPPER
network mailing list, this percentage could be lower if >1 pharmacist
per pharmacy filled out the questionnaire. The response rate is con-
sidered low for web-based questionnaires.27,28 However, it is rea-
sonable for the UPPER network, with a usual response rate of
10–15% in their surveys.22,29 Nonresponse bias was possible: phar-
macists with limited interest and knowledge on this topic possibly
did not participate resulting in a higher average knowledge score. By
contrast, participants received additional information on the topic as
incentive, which could have attracted pharmacists with limited
knowledge resulting in a lower mean level of knowledge. When com-
paring characteristics of respondents with Dutch national data from
2004, a high frequency of female pharmacists was noted in our sam-
ple.30 A likely explanation is that in the past 15 years, the mal-
e/female ratio among community pharmacists in the Netherlands has
changed, as described by the Dutch Foundation for Pharmaceutical
Statistics.31
To test the level of knowledge of participants, we used 6 multi-
ple-choice questions. Thus, the score on the knowledge test only
gives a global impression about the pharmacists' knowledge. Never-
theless, in our opinion, the designed questions represent minimal
requirements for providing proper care in these patients.
4.2 | Implications for practice and future research
The results of this study indicate a compelling need for more education
on medication safety in patients with hepatic impairment. It is rec-
ommended to provide basic knowledge and create awareness for this
patient group during the pharmacy and medicine undergraduate stud-
ies and provide more advanced practice-based education in a
postgraduate course. In a couple of years, this study and especially the
knowledge test could be repeated to evaluate improvement. In further
research, one could also study the actual care provided by the pharma-
cists. For example, by assessing how pharmacists manage alerts in their
CDSS on medication safety in patients with hepatic impairment or by
examining if pharmacists ask their customers about liver disease before
they recommend a nonsteroidal anti-inflammatory drug.
To improve medication safety in patients with hepatic impair-
ment, pharmacists and prescribers can be supported by their CDSS.26
The practical guidance on medication safety in patients with hepatic
impairment was published in English, yet only integrated in CDSS in
the Netherlands.10 This study provides valuable insights for other
countries that want to integrate decision support for safe use of medi-
cation in hepatic impairment. To make optimal use of clinical decision
support, the exchange of the diagnosis and severity of hepatic impair-
ment between healthcare professionals needs to be improved. Phar-
macotherapy meetings between GPs and pharmacists can help. These
meetings could be used to discuss practicalities limiting the exchange
of the diagnosis and severity of hepatic impairment and to improve
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involvement and knowledge among participants. Previous studies
have shown the positive impact of high-quality pharmacotherapy
meetings in optimizing pharmacotherapy.32,33
Medication-related problems are very common in patients with
cirrhosis. A recent single-centre trial showed that more than half of
medication-related problems could be resolved by a pharmacist-led
medication review.5 These results are promising and the guidance we
developed can support pharmacists. However, for large-scale imple-
mentation of pharmacists-led medication reviews in these patients,
there are still some barriers to overcome as we demonstrated in this
study.
5 | CONCLUSION
We showed that the level of knowledge of community pharmacists on
medication safety in patients with hepatic impairment is low and that
additional education is needed and wanted. The majority of pharma-
cists encounter patients with hepatic impairment regularly; however,
when providing care in these patients they frequently experience dif-
ficulties in the contact with other healthcare professionals and lack
essential patient information. If these issues are resolved, pharmacists
can play a more active role in ensuring safe and optimal medication
use and prevention of medication-related problems in patients with
hepatic impairment.
COMPETING INTERESTS
There are no competing interests to declare.
CONTRIBUTORS
R.W. and M.A. drafted the manuscript. A.B., K.T. and S.B. participated
in data analysis and interpretation and critically revised the manu-
script. Supervision was done by A.B. and S.B. All authors approved the
final version of the manuscript.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
ORCID
Rianne A. Weersink https://orcid.org/0000-0001-6996-894X
Anthonius de Boer https://orcid.org/0000-0002-9485-8037
Katja Taxis https://orcid.org/0000-0001-8539-2004
REFERENCES
1. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose
adjustment in patients with liver disease. Drug Saf. 2005;28(6):
529-545.
2. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients
with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147-
1161.
3. Franz C, Egger S, Born C, Rätz Bravo A, Krähenbühl S. Potential drug-
drug interactions and adverse drug reactions in patients with liver cir-
rhosis. Eur J Clin Pharmacol. 2012;68(2):179-188.
4. Weersink RA, Taxis K, Drenth JPH, Houben E, Metselaar HJ,
Borgsteede SD. Prevalence of drug prescriptions and potential safety
in patients with cirrhosis: a retrospective real-world study. Drug Saf.
2018;1-8.
5. Hayward KL, Patel PJ, Valery PC, et al. Medication-related problems
in outpatients with decompensated cirrhosis: opportunities for harm
prevention. Hepatol Commun. 2019;3(5):620-631.
6. Hilscher MB, Odell LJ, Myhre LJ, Prokop L, Talwalkar J. The pharma-
cotherapy of cirrhosis: concerns and proposed investigations and
solutions. J Clin Pharm Ther. 2016;41(6):587-591.
7. Chang Y, Burckart GJ, Lesko LJ, Dowling TC. Evaluation of hepatic
impairment dosing recommendations in FDA-approved product
labels. J Clin Pharmacol. 2013;53(9):962-966.
8. Failings in treatment advice, SPCs and black triangles. Drug Ther Bull.
2001;39(4):25-27.
9. Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acet-
aminophen) be administered to patients with liver impairment? Br J
Clin Pharmacol. 2016;81(2):210-222.
10. Weersink R, Bouma M, Burger D, et al. Evidence-based recommenda-
tions to improve the safe use of drugs in patients with liver cirrhosis.
Drug Saf. 2018;41(6):603-613.
11. Weersink RA, Bouma M, Burger DM, et al. Safe use of proton pump
inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018;84(8):
1806-1820.
12. Watkins K, Wood H, Schneider CR, Clifford R. Effectiveness of imple-
mentation strategies for clinical guidelines to community pharmacy: a
systematic review. Implement Sci. 2015;10(1):151-174.
13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R.
Transection of the oesophagus for bleeding oesophageal varices. Br J
Surg. 1973;60(8):646-649.
14. Rossi S, Assis DN, Awsare M, et al. Use of over-the-counter analge-
sics in patients with chronic liver disease. Drug Saf. 2008;31(3):
261-270.
15. Nguyen D, Banerjee N, Abdelaziz D, Lewis JH. Trainees' attitudes and
preferences toward the use of over the counter analgesics in patients
with chronic liver disease. Adv Pharmacoepidemiol Drug Saf. 2014;3:
167-172.
16. Hong YM, Yoon KT, Heo J, et al. The prescription pattern
of acetaminophen and non-steroidal anti-inflammatory
drugs in patients with liver cirrhosis. J Korean Med Sci. 2016;31(10):
1604-1610.
17. Gauthier TP, Moreira E, Chan C, et al. Pharmacist engagement within
a hepatitis C ambulatory care clinic in the era of a treatment revolu-
tion. J am Pharm Assoc. 2016;56(6):670-676.
18. Kolor B. Patient education and treatment strategies implemented at a
pharmacist-managed hepatitis C virus clinic. Pharmacotherapy. 2005;
25(9):1230-1241.
19. Mohammad RA, Bulloch MN, Chan J, et al. Provision of clinical phar-
macist services for individuals with chronic hepatitis C viral infection:
joint opinion of the GI/liver/nutrition and infectious diseases practice
and research networks of the American College of Clinical Pharmacy.
Pharmacotherapy. 2014;34(12):1341-1354.
20. Mark MP. The general pharmacy work explored in the Netherlands.
Pharm World Sci. 2008;30(4):353-359.
21. van de Pol JM, Geljon JG, Belitser SV, Frederix GWJ, Hövels AM,
Bouvy ML. Pharmacy in transition: a work sampling study of commu-
nity pharmacists using smartphone technology. Res Soc Admin Pharm.
2019;15:70-76.
22. Koster ES, Blom L, Philbert D, Rump W, Bouvy ML. The Utrecht phar-
macy practice network for education and research: a network of com-
munity and hospital pharmacies in the Netherlands. Int J Clin
Pharmacol. 2014;36(4):669-674.
23. Roederer MW, Van Riper M, Valgus J, Knafl G, McLeod H. Knowl-
edge, attitudes and education of pharmacists regarding pharmaco-
genetic testing. Pers Med. 2012;9(1):19-27.
WEERSINK ET AL. 7
24. Baars MJH, Henneman L, ten Kate LP. Deficiency of knowledge
of genetics and genetic tests among general practitioners, gyne-
cologists, and pediatricians: a global problem. Genet Med. 2005;7(9):
605-610.
25. Warholak-Juarez T, Rupp MT, Salazar TA, Foster S. Effect of patient
information on the quality of pharmacists' drug use review decisions.
Journal of the American Pharmaceutical Association (1996). 2000;40(4):
500-507.
26. Kuperman GJ, Bobb A, Payne TH, et al. Medication-related clinical
decision support in computerized provider order entry systems: a
review. J am Med Inform Assoc. 2007;14(1):29-40.
27. Nulty DD. The adequacy of response rates to online and paper sur-
veys: what can be done? Assess Eval High Educ. 2008;33(3):301-314.
28. Cunningham CT, Quan H, Hemmelgarn B, et al. Exploring physician
specialist response rates to web-based surveys. BMC Med Res Met-
hodol. 2015;15(1):32-40.
29. Heringa M, Floor-Schreudering A, Wouters H, De Smet PAGM,
Bouvy ML. Preferences of patients and pharmacists with regard to
the Management of Drug–Drug Interactions: a choice-based conjoint
analysis. Drug Saf. 2018;41(2):179-189.
30. Kooy MJ, Dessing WS, Kroodsma EF, et al. Frequency, nature and
determinants of pharmaceutical consultations provided in private by
Dutch community pharmacists. Pharm World Sci. 2007;29(2):81-89.
31. Foundation for Pharmaceutical Statistics. Openbaar Apotheker wordt
Vrouwenberoep. Pharm Weekbl. 2015;150:9.
32. Eimers M, van der Aalst A, Pelzer B, Teichert M, de Wit H. Leidt een
goed FTO tot beter voorschrijven? Huisarts Wet. 2008;51(7):
340-345.
33. Florentinus SR, Rv H, Kloth MEM, et al. The effect of pharmacother-
apy audit meetings on early new drug prescribing by general practi-
tioners. Ann Pharmacother. 2007;41(2):319-324.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article:Weersink RA, Abadier M, de Boer A,
Taxis K, Borgsteede SD. Medication safety in patients with
hepatic impairment: A survey of community pharmacists’
knowledge level and their practice in caring for these patients.
Br J Clin Pharmacol. 2020;1–8. https://doi.org/10.1111/bcp.
14177
8 WEERSINK ET AL.
